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Goals and Challenges of
Proteomics
Proteomics is defined as the system-wide
characterization of all the proteins in an
organism in terms of their sequence,
localization, abundance, post-translational
modifications, and biomolecular interac-
tions. Modern proteomic investigations
are increasingly quantitative and compre-
hensive [1]. Examples include the relative
quantification of over 4,000 proteins in
haploid and diploid yeast, which identified
the pheromone signaling pathway as
enriched in differential abundance [2];
determination of site- and time-specific
dynamics of more than 6,000 phosphory-
lation sites of HeLa cells stimulated with
epidermal growth factor [3]; and charac-
terization of 232 multiprotein complexes
in Saccharomyces cerevisiae, which proposed
new cellular roles for 344 proteins [4].
Such investigations are now successfully
utilized in functional biology [5,6], geno-
mics [7,8], and biomedical research [9].
Challenges of proteomic studies stem
from the complexity of the proteome and
to its broad dynamic range. For example,
the human genome contains around
20,000 protein coding genes. Their trans-
lation, combined with splicing or proteol-
ysis, yields an estimated 50,000–500,000
proteins, and over 10 million different
protein forms can be derived by somatic
DNA rearrangements and post-transla-
tional modifications [10]. The abundance
of protein species in human plasma spans
more than 10 orders of magnitude [11].
Unlike oligonucleotides, proteins cannot
be amplified, and therefore the objectives
of proteomics are achieved by sensitive
and scalable technologies identifying and
quantifying proteins [12]. The overall
mass spectrometry–based proteomic work-
flow is summarized in Figure 1.
Experimental Design
Quantitative proteomic investigations
are conducted in the context of biological
variation [13], technical variation due to
sample processing and spectral acquisition,
and ambiguities of spectral interpretation.
Statistical experimental design [14,15]
accounts for these sources of variation.
The first goal of experimental design is to
avoid biases [16,17] (i.e., systematic errors
in interpretation) by clearly defining the
populations of interest, matching the
individuals with respect to the confound-
ing factors, randomizing the selection of
matched individuals from the population,
and randomizing sample allocation to the
processing steps. The second goal is to
ensure efficiency (i.e., minimal random
variation and uncertainty for a given cost)
by choosing an appropriate number of
biological and technical replicates, and by
allocating the replicates to experimental
resources in balanced blocks. The steps of
the statistical experimental design are
summarized in Figure 2.
Mass Spectrometry–Based
Measurements
Global Label-Free LC-MS/MS
Workflow
Mass spectrometry is currently the only
technology for protein identification and
quantification that is both high-accuracy
and high-throughput [18–20]. Although
many alternatives exist, shotgun liquid
chromatography coupled with tandem
mass spectrometry (LC-MS/MS; overview
in Figure 3) is most frequently used. Mass
spectrometry is better amenable to char-
acterizing peptides; therefore, LC-MS/
MS starts by enzymatically digesting pro-
teins into a peptide mixture. Next, liquid
chromatography (LC) separates the pep-
tides, andthe separated peptides are ionized
and further separated by the mass spec-
trometer according to their mass-to-charge
ratio in a mass spectrum (MS). The mass
spectra obtained from the same sample at
different elution times form an LC-MS run,
and intensities of MS peaks, are related to
peptide abundance. For identification, the
mass spectrometer isolates the biological
material of selected MS peaks, subjects it to
collision energy or another type of frag-
mentation, and separates the resulting
fragments in a secondary (MS/MS) mass
spectrum. The distances between the MS/
MS peaks are used to infer the amino acid
sequence of the parent MS peak. Since
abundant MS1 peaks are more likely to be
selected for fragmentation, relative peptide
quantification can also be achieved by
counting the number of identified MS/
MS spectra.
An LC-MS/MS experiment can identify
and quantify thousands of proteins in
complex mixtures. It requires minimal
manipulation of the sample, and minimal
prior information regarding its composi-
tion. However, the workflow has a number
of deficiencies. Enzymatic digestion in-
creases the complexity of the mixture. For
example, a proteome comprising 5,000
proteins is expected to yield over 250,000
tryptic peptides, and minor cleavage and
fragmentations of abundant proteins can
obscure major events of low-abundant
proteins, complicating the interpretation
[21]. Dynamic range of mass spectrometers
is limited to 3–4 orders of magnitude, and
the direct LC-MS/MS analysis is biased
towards most abundant peptides [22].
Technical variation can further undermine
the identification and the quantification
steps. A variety of extensions to this basic
workflow have therefore been proposed.
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Label-Based Quantification
The LC-MS/MS workflow is enhanced
by labeling samples from different condi-
tions metabolically (e.g., with SILAC [23],
where stable isotopes are included in the
growth medium of an organism), or chem-
ically (e.g., with iTRAQ [24] or TMT [25],
where reacting chemical labels are applied
during sample processing). Samples with
different labels are combined and analyzed
by a mass spectrometer within a single LC-
MS run. Peaks from the samples are sub-
sequently recognized by label-induced mass
shifts in MS (SILAC) or MS/MS (iTRAQ,
TMT) spectra, and used for relative quan-
tification. Labeling enables within-run com-
parisons of protein abundance, and im-
proves the precision of quantification.
Experimental design can further gain effi-
ciencythroughoptimalallocationofsamples
to the labels, e.g., in reciprocal or reference
designs [26] or by using labeled synthetic
peptides as references. However, labeling
requires extra sample manipulation and
increases the complexity of the sample.
Overcoming Limits of Dynamic
Range: Targeted Workflows
The complexity of a biological mixture
can be overcome by fractionation [27];
however, this severely undermines the
throughput. A valuable alternative is
selected reaction monitoring (SRM) (also
referred to as multiple reaction monitor-
ing, MRM), a targeted workflow where
the mass spectrometer isolates a set of pre-
defined peptides and their fragments
during mass analysis [28–31]. The result-
ing peptide-fragment pairs (called transi-
tions) are used for quantification. Since the
isolation is highly specific, SRM enables
the most sensitive mass spectrometry–
based quantification currently available.
For example, proteins expressed with
fewer than 50 copies/cell were quantified
in total yeast lysates [32]. As shown in
Figure 3, SRM can be conducted in
conjunction with both label-free and
label-based workflows. The drawback of
targeted workflows is that they only
quantify a priori known proteins, require
optimized experimental protocols, and
limit the number of measurements per
run to a few hundreds. Further techno-
logical developments [33] and optimal
experimental designs [34] will help allevi-
ate these drawbacks.
Computation and Statistics
Identification of Peptides and
Proteins
The computational and statistical anal-
yses of the acquired spectra are illustrated
in Figure 4. With the shotgun LC-MS/MS
workflow, the first step is to identify
Figure 1. Quantitative mass spectrometry–based proteomic workflow. The workflow requires a tight integration of biological and
experimental (red) and computational and statistical (yellow) analysis steps.
doi:10.1371/journal.pcbi.1002277.g001
Figure 2. Experimental design. Statistical experimental design consists of (a) defining the populations of interest, (b) randomly selecting biological
replicates from the population and (optionally) matching confounding factors, (c) randomly allocating biological samples to spectral acquisition and
(optionally)groupingthesamples in balancedblocksforjointprofiling, and(d)(optionally) acquiringtechnical replicatemeasurementsonthebiological
samples. Replication, randomization, and blocking are necessary to avoid biases and maximize the efficiency of the experiment.
doi:10.1371/journal.pcbi.1002277.g002
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to the MS/MS spectra. This has received
much attention from both algorithmic and
statistical viewpoints [35–37]. A predom-
inant approach is the database search,
which compares each observed spectrum
to the theoretical spectra predicted from a
genomic sequence database (or to the
previously identified experimental spectra
in a library [38]), and reports the best-
scoring peptide-spectrum match (PSM).
Emerging alternatives are de novo identifi-
cations and hybrid searches [39,40].
Due to the stochastic nature of the MS/
MS spectra [41], and to deficiencies of
scoring functions and databases, the best-
scoring PSMs are not necessarily correct.
Statistical characterization of the identifi-
cations is necessary, and is now required
by most journals [42]. This problem is
frequently formalized as controlling the
false discovery rate (FDR) in the list of
reported PSMs [43,44]. Representative
methods for controlling FDR are two-
group models, which view the reported
PSMs as a mixture of correct and incorrect
identifications [45], and methods utilizing
decoy databases [46]. Typically, only
around 30% of MS/MS spectra are
confidently identified, and developing
improved methods is an active area of
research.
The task of identification extends to
inferring peptides and proteins in the
sample from the identified MS/MS spec-
tra. This is challenging due to the ‘‘many-
to-many’’ mapping of peptides to proteins,
and of MS/MS spectra to peptides.
Inference must enable parsimonious re-
sults, while maintaining the sensitivity and
characterizing the confidence in the iden-
tifications. The problem of protein infer-
ence is not entirely solved. For example,
arguments exist in favor [47] and against
[48] reporting single-peptide protein iden-
tifications, and in favor [49] and against
[50] the exclusive use of protease-specific
peptides.
A typical experiment generates hun-
dreds of thousands of MS/MS spectra,
and open-source and commercial pipelines
such as the Trans-Proteomic Pipeline [51]
streamline spectral handling and interpre-
tation through common infrastructure.
Quantification of Spectral Features
The next step in quantitative label-free
LC-MS/MS experiments is to locate and
quantify MS peaks, annotate them with
peptide and sequence identities, and
Figure 3. Mass spectrometry–based measurements. (a) Sample processing. Label-free quantification requires minimal sample manipulation,
and acquires spectra from each sample in a separate mass spectrometry run. Label-based quantification varies in the timing and type of the labeling
steps, but always simultaneously profiles two or more biological samples within a run. (b) Global label-free workflows achieve relative quantification
by comparing counts of MS/MS spectra, or intensities of MS peaks between runs. Global label-based workflows compare intensities of reporter MS/
MS fragments (iTRAQ) or MS peaks (SILAC, synthetic peptides). (c) Targeted workflows are an alternative to global quantification. They are most
sensitive, but require an a priori knowledge of the proteins of interest, and of the technological characteristics of their peptides. Label-free targeted
experiments compare intensities of transitions between runs, and label-based experiments within a run.
doi:10.1371/journal.pcbi.1002277.g003
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between runs [52]. Label-based workflows
with MS quantification (e.g., SILAC)
search for pairs of peaks with known mass
shifts that correspond to a same peptide.
Workflows with MS/MS quantification
(e.g., iTRAQ) locate and quantify reporter
MS/MS fragments. All these tasks can be
made difficult by irregular, overlapped,
and missing peaks, chromatographic var-
iations between runs, and incomplete and
incorrect identifications. As a result, only a
subset of the identified proteins is typically
quantified [53]. A variety of signal pro-
cessing software tools are reviewed in [54],
and the representative ones are OpenMS
[55] for label-based quantification and
MaxQuant [56] for quantification with
SILAC.
Targeted SRM experiments sidestep the
need for identifying and aligning peaks,
and signal processing focuses on peak
detection, quantification, and annotation.
However, difficulties can arise with over-
lapped or suppressed signals or incorrectly
calibrated transitions, and computational
methods can help filter out poor quality
transitions [57,58]. Pipelines such as
Skyline [59,60] and ATAQS [61] stream-
line these tasks.
Frequently, sample handling induces
differences in the quantitative signals
between runs, and global between-run
normalization is necessary to distinguish
true biological changes from these arti-
facts. Two common approaches to global
normalization are sample-based and con-
trol-based. Sample-based normalization,
e.g., quantile normalization or normaliza-
tion based on the total ion current, makes
the best use of the data, but assumes that
the majority of features do not change in
abundance [62]. Control-based normali-
zation in preferred in experiments with
few measurements or many biological
changes.
Finding Differentially Abundant
Proteins
Typical statistical goals of quantitative
proteomics are protein quantification, i.e.,
estimation of protein concentration in a
sample on a relative or absolute scale, and
class comparison, i.e., determination of
proteins that change in average abun-
dance between conditions. To achieve
this, it is often necessary to summarize
the quantitative information across all the
features that pertain to a protein. One
such approach is spectral counting [63],
which is based on the insight that in global
LC-MS/MS peaks from abundant pro-
teins are more frequently selected for
fragmentation, and uses the number of
identified MS/MS spectra as a proxy for
the abundance. The approach involves
minimal signal processing; however, it
requires specialized statistical modeling, is
limited to finding large changes among
abundant proteins, and is most successful
with mixtures of low complexity, e.g., for
determination of protein complexes [64].
Alternative approaches are based on
summarizing signals from quantified spec-
tral peaks. With other technologies such as
gene expression microarrays, similar sum-
marization is performed by some form of
averaging, e.g., with Robust Multiarray
Averaging (RMA) [65]. Unfortunately,
averaging fails to produce accurate results
in mass spectrometry–based proteomics.
Length, charge, and other chemical prop-
erties of peptides greatly affect the quality
of the signals, and averaging obscures
these difference in information content.
A more successful summarization re-
quires probabilistic modeling, which rep-
resents all features of a protein and
characterizes their variation. A diverse
range of such models has been proposed,
and there is no single generally accepted
procedure. The models differ in using raw
or log-transformed intensities, comparing
groups in terms of ratios or differences,
and using general-purpose [66] or special-
ized [67] classes of statistical models.
Important aspects are accurate represen-
tation of the experimental design and of
within-run groupings of peaks in label-
based workflows, treatment of missing
data (e.g., using specialized [68] or gener-
al-purpose [69,70] techniques), incorpo-
rating confidence in feature identifications
[71], expanding the scope of conclusions
to the underlying populations or restricting
Figure 4. Computation and statistics. Analysis of the acquired spectra includes (a, b) signal processing, (c, d) significance analysis, and (e–h)
downstream analysis. Methods in (a–d) must reflect the technological properties of the workflows. Methods in (e–h) are technology-independent and
are similar to the analysis of gene expression microarrays, but their use is affected by uncertainty in protein identities and the incomplete samplingo f
the proteome.
doi:10.1371/journal.pcbi.1002277.g004
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controlling the FDR in the list of differen-
tially abundant proteins. In some cases,
e.g., in samples enriched in post-transla-
tional modifications, changes in peak
intensities can be due to both differential
abundance and differential modifications.
Comparisons at the feature level are then
more appropriate; however, they should
be adjusted for the overall changes in
protein abundance [72].
Given the diversity of experimental
designs and analysis steps, all these tasks
can rarely be performed in a fully
automated fashion, and consultations with
statisticians are highly recommended.
Downstream Analysis
The high-throughput nature of proteo-
mic data is similar to that of gene
expression microarrays, and many down-
stream analysis methods can also be
applied in proteomics [73]. In particular,
all analyses benefit from data visualization
[74]. Unsupervised class discovery helps find
functionally related proteins, or biological
samples homogeneous with respect to the
quantitative protein profiles. Supervised
class prediction, e.g., prediction of the disease
status of a patient based on his or her
protein abundance [75], and its thorough
validation [76], are the required steps for
discovery of biomarkers of disease.
Enrichment analysis tests whether pre-
specified sets of proteins, e.g., those
sharing a function, change in abundance
more systematically than as expected by
chance. This is referred to as pathway
analysis when the protein set forms a
pathway. The analysis investigates hypoth-
eses that are more directly relevant to the
biological function, and can help detect
small but consistent changes in abundance
within the set. Many enrichment analysis
methods exist and are systematically
reviewed in [77,78], and representative
examples are the hypergeometric (equiva-
lently, Fisher’s exact) test and Gene Set
Enrichment Analysis (GSEA) [79]. A
particular challenge in proteomics is to
map the protein identitifiers to gene-
centric knowledge bases. The tools for this
task are reviewed in [80], and a represen-
tative one is DAVID [81].
A frequently asked question is the
correlation between the expression of pro-
tein-coding genes and the abundances of
the corresponding proteins [82–84]. Many
studies reported that in bacteria and uni-
cellular eukaryotes, proteins and mRNA
exhibit moderate correlation in a steady
state (Pearson correlation of the order of
0.4), but it improves to the order of 0.6–0.7
for proteins that are directly affected by a
relevant condition or a stress [2]. An even
lower correlation has been historically
reported for multi-cellular eukaryotes; how-
ever, technological improvements now also
point to a steady state correlation in human
samples of the order of 0.4 [85].
The moderate correlation of transcript
and protein abundance indicates a major
role of post-translational regulation in the
activity of the cell. Therefore, the best
functional insight can be obtained by
combining measurements across technol-
ogies, and searching for broader groups of
genes, proteins, and metabolites forming
regulatory relationships [86,87]. Such
integrative studies are increasingly appear-
ing [88,89]. They remain challenging,
however, due to the complexity of the
underlying processes, incomplete sampling
of the proteome, uncertainty in protein
identities and difficulties of resolving
multiple proteomic, genomic, and techno-
logical identifiers across platforms. New
specialized methods and algorithms are
needed to address these challenges.
Outlook
Despite the challenges, mass spectrom-
etry–based proteomics continues to bring
high promise for basic science and clinical
research [90]. Several studies recently
demonstrated that with appropriate care
and training, it is now possible to accu-
rately and reproducibly identify and quan-
tify proteins across laboratories and instru-
ment platforms [91–93]. In shotgun
proteomics, most repeatable peptide iden-
tifications corresponded to enzyme-specif-
ic cleavage sites, intense MS peaks, and
proteins that generated many distinct
peptides. Targeted quantification could
reproducibly detect low mg/ml protein
concentrations in unfractionated plasma.
To date, only 65% of all predicted
human proteins have been reliably ob-
served by mass spectrometry [90]. There-
fore, future experimental developments
will focus on improving the sensitivity,
reproducibility, and comprehensiveness of
protein identifications, and the sensitivity
and accuracy of quantification. All studies
consistently emphasize the key role of
computation [94]. Future computational
efforts will involve the development of
proteome-centric knowledge bases such as
neXtProt (http://www.nextprot.org/), re-
positories of experimental data, and the
development of methods for optimal
experimental design and data interpreta-
tion. Venues such as RECOMB Satellite
Conference on Computational Proteomics
[95] aim at closing the communication
gap between biologists, chemists, and
statisticians, and enable integrative and
collaborative research.
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